Diabetic nephropathy (DN) is a severe microvascular complication of diabetes mellitus that is a leading cause of end-stage renal disease and substantial morbidity. Because current therapeutic options have limited efficacy and can produce adverse effects, there is interest in complementary and alternative agents. This study combined large-scale population data with multi-omics bioinformatics to explore potential mechanisms by which Lianmei granules (LMG) may affect DN.
The population analysis used data from the National Health and Nutrition Examination Survey (NHANES) spanning 2001–2023 and included 44,090 participants. Given the cross-sectional design of NHANES, the investigators operationalized diabetic nephropathy as the coexistence of a diagnosed diabetes condition and urine albumin-to-creatinine ratio (UACR) ≥ 30 mg/g documented in matched adjacent NHANES cycles. This choice aimed to reduce potential false positives driven by single measurements and to better approximate clinical diagnostic practice in the absence of longitudinal follow-up.
Multivariate logistic regression was applied to identify independent risk factors associated with this DN definition. The authors explicitly note that the analytic approach does not represent longitudinal confirmation of DN and is subject to the usual limitations inherent in cross-sectional data.
Multivariate regression identified several independent risk factors for the DN definition used in this analysis. Reported associations included:
These findings quantify demographic and clinical correlates of the NHANES-derived DN phenotype within the sampled population.
To explore putative molecular mechanisms of LMG in DN, the investigators screened active compounds using established databases, including the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) and others. Screening yielded 215 active compounds attributed to LMG. These compounds were cross-referenced with DN-related gene sets to identify overlapping targets, resulting in 64 potential DN-related targets associated with LMG compounds.
From the overlapping targets, the study identified core hub targets within protein-protein interaction networks. Reported core targets in the abstract include prostaglandin-endoperoxide synthase 2 (PTGS2), EGFR, ESR1, CYP3A4, and matrix metallopeptidase 9 (MMP9).
Gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses indicated that these targets are primarily involved in cellular response processes and hormone signaling pathways. The abstract emphasizes involvement in cellular responses and hormone-related signaling but does not list specific enriched pathways or p-values in the source document.
The investigators performed differential expression analysis using dataset GSE96804. This analysis identified 615 differentially expressed genes between DN samples and controls. The abstract does not enumerate these genes in full.
An immune infiltration analysis was also carried out and demonstrated statistically significant differences in immune cell distribution between DN and control groups, suggesting an immunological component to the disease state or its transcriptomic signature. Specific cell types or quantitative infiltration metrics are not provided in the abstract text in the source.
Molecular docking and molecular dynamics simulations were performed to evaluate interactions between LMG compounds and target proteins. The abstract states that these computational simulations were conducted but does not report specific docking scores, binding poses, stability metrics, or which compound–target pairs were prioritized. No experimental validation results are reported in the abstract.
Key methodological limitations reported or implied by the source include the cross-sectional nature of the NHANES analysis and the operational DN definition based on matched adjacent cycles rather than longitudinal clinical follow-up. These design aspects limit causal inference and the ability to confirm incident DN. The abstract summarizes bioinformatics and computational findings but does not provide experimental or clinical outcome data demonstrating efficacy of LMG in DN.
Taken together, the study integrates population-level epidemiology with network pharmacology, transcriptomics, immune profiling, and molecular simulation to generate hypotheses about how Lianmei granules might interact with molecular pathways relevant to diabetic nephropathy. The source indicates areas for further work—particularly longitudinal clinical studies and experimental validation of predicted compound–target interactions—but details of such follow-up are not provided in the abstract.